Medisafe

Medication reminder and management app with interaction warnings and refill tracking.

Pricing: custom
Open source: No

Editorial review

Medisafe has not yet been editorially reviewed. User reviews and published field data below are unaffected — we say so rather than implying an editorial verdict.

Facts & attributes

Every value carries its evidence state. “—” means unknown — never a silent default (P-02).

Identity · Taxonomy

Tags(open-source;cloud-native): medication-adherence, patient-engagement, pharma, digital-healthVerification pending

Platform · Deployment

Delivery model(SaaS;self-hosted;desktop;mobile;embedded;managed-cloud;appliance): SaaS, mobileVerification pending

Pricing · Licensing

Pricing model(free;subscription;usage;seat;asset;transaction;revenue-share;perpetual;custom): customVerification pending

Features · Product · Fit

Core capabilities(authoring;automation;analytics): behavior-driven digital patient engagement, medication adherence improvement, extension of patient support programs into daily patient behavior, therapy persistence and adherence measurement, digital companions for patientsVerification pending

Audience · Use · Case

Best for(Neutral editorial summary): Pharma brands scaling patient support programs and measuring medication-adherence outcomes across therapies and marketsVerification pending
Company-size fit(individual;SMB;mid-market;enterprise): enterpriseVerification pending
Primary use cases(build;monitor;automate): For Pharma: scale patient support across brands and markets, For Providers: support patients between visits, For Patients: manage medications and navigate treatmentVerification pending
Skill level(beginner;intermediate;advanced;specialist): specialistVerification pending

Lifecycle · Versioning

Maintenance status(active;maintenance;deprecated;EOL;archived): activeVerified

Vendor · Maintainer

Vendor type(commercial;foundation;community;government;consortium;individual): commercialVerification pending

User reviews

Review policy

No published reviews yet.